0
ALX Oncology Holdings Inc. Banner Image

ALX Oncology Holdings Inc.

  • Ticker ALXO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
ALX Oncology Holdings Inc. Logo Image
  • 11-50 Employees
  • Based in South San Francisco, California
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain withMore an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors.
ALX Oncology Holdings Inc.

Most Recent Annual Report

ALX Oncology Holdings Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

ALX Oncology Holdings Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!